Results 191 to 200 of about 25,426 (206)

PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy

Molecular Cancer Therapeutics, 2013
Abstract Nasopharyngeal carcinoma is a rare but highly invasive cancer. As options of agents for effective combination chemoradiotherapy for advanced nasopharyngeal carcinoma are limited, novel therapeutic approaches are desperately needed.
Chow, Pak Hong Jeremy, Man, Wing Yu, Mao, Mao, Chen, Han, Cheung, Florence, Nicholls, John M., Tsao, Sai Wah, Lung, Maria Li, Poon, Randy Yat Choi   +8 more
openaire   +4 more sources

NR1D1 enhances oxidative DNA damage by inhibiting PARP1 activity

Molecular and Cellular Endocrinology, 2017
Cancer cells exhibit an elevated intracellular level of reactive oxygen species (ROS) because of their accelerated metabolism, mitochondrial dysfunction, and antioxidant deficit. The oxidative stress in cancer cells may provide clinical benefits, which can be associated with a better response to anticancer therapies.
Na-Lee, Ka, Tae-Young, Na, Mi-Ock, Lee
openaire   +2 more sources

PARG inhibition induces nuclear aggregation of PARylated PARP1

2023
Abstract PARG inhibitors are currently under clinical development for the treatment of DNA repair-deficient cancers, however, their precise mechanism of action is still unclear. Here we report that PARG inhibition causes increased nuclear PARylated PARP1 that limits PARP1 chromatin binding in response to DNA damage. This PARylated PARP1
Sateja Paradkar, Julia Purcell, Annie Cui, Sam Friedman, Ranjini Sundaram, Ryan Jensen, Ranjit Bindra   +6 more
openaire   +1 more source

XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a

Cancer Letters, 2021
Patient mortality rates have remained stubbornly high for the past decades in small cell lung cancer (SCLC) because of having no standard targeted therapies with confirmed advantages at present. Poly [ADP-ribose] polymerase (PARP) inhibitors have shown promise in preclinical models but have had unsatisfactory clinical results in SCLC.
Jingya, Wang, Tao, Sun, Zhaoting, Meng, Liuchun, Wang, Mengjie, Li, Jinliang, Chen, Tingting, Qin, Jiangyong, Yu, Miao, Zhang, Zhixin, Bie, Zhiqiang, Dong, Xiangli, Jiang, Li, Lin, Cuicui, Zhang, Zhujun, Liu, Richeng, Jiang, Guang, Yang, Lin, Li, Yan, Zhang, Dingzhi, Huang   +19 more
openaire   +2 more sources

Inhibition of PARP1 Increases IRF-dependent Gene Transcription in Jurkat Cells

Current Medical Science, 2019
Poly(ADP-ribose) polymerase 1 (PARP1) plays important roles in the regulation of transcription factors. Mounting evidence has shown that inhibition of PARP1 influences the expression of genes associated with inflammatory response. Interferon regulatory factor 1 (IRF1) is a critical transcription factor for the development of both the innate and ...
Cheng, Wang, Meng, Du, Dan, Huang, Kun, Huang, Kai, Huang   +4 more
openaire   +2 more sources

TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer

Human Cell, 2020
Endometrial cancer (EC) is one of the most common cancers among females worldwide. Advanced stage patients of EC have poor prognosis. Inevitable side effects and treatment tolerance of chemotherapy for EC remain to be addressed. Our results in this study showed that EC cells with higher tumor necrosis factor receptor-associated factor 4 (TRAF4 ...
Liulin, Tang, Min, Wang, Li, Jiang, Chengying, Zeng   +3 more
openaire   +2 more sources

Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells

Anti-Cancer Drugs
Liver cancer is a prevalent malignant tumor globally. The newly approved first-line drug, donafenib, is a novel oral small molecule multi-tyrosine kinase inhibitor that has significant antitumor effects on liver cancer. This study aims to investigate the antitumor effects of donafenib on liver cancer and to explore its potential mechanisms.
Jiuliang, Jiang, Pingping, Yang, Xinyu, Xu, Huixiong, Yuan, Haitao, Zhu   +4 more
openaire   +2 more sources

Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1

Molecular and Cellular Biochemistry, 2005
Poly(ADP-ribose) polymerases or PARPs are a family of NAD(+)-dependent enzymes that modify themselves and other substrate proteins with ADP-ribose polymers. The founding member PARP 1 is localized predominantly in the nucleus and is activated by binding to DNA lesions.
Tsung-Yin J, Yeh, Juan I, Sbodio, M T Audrey, Nguyen, Tobias N, Meyer, Ray M, Lee, Nai-Wen, Chi   +5 more
openaire   +2 more sources

Protein Kinase D1 Translocates PARP1 to the Membrane and Is Associated With Increased Sensitivity to Cell Viability Inhibition by PARP1 Inhibitor Olaparib

The Prostate
ABSTRACT Background There are four FDA‐approved poly (ADP‐ribose) polymerase inhibitors (PARPi) for treating metastatic castration‐resistant prostate cancer. However, dose‐limiting toxicities may reduce efficacy when treatment is de‐escalated.
Sanjeev Shukla, Joseph McGrath, Robert Willis, Arjun Venkatesh, Reynier D. Rodriguez Rosales, Jean‐Pierre Kanumuambidi, Mario Mietzsch, Robert McKenna, Jonathan Chardon‐Robles, K. C. Balaji   +9 more
openaire   +1 more source

Muscle PARP1 inhibition extends lifespan through AMPKα PARylation and activation in Drosophila

Proceedings of the National Academy of Sciences of the United States of America, 2023
Shanshan Guo, Shuang Zhang, Yixiao Zhuang   +2 more
exaly